Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Receivables (2020 - 2025)

RxSight's Change in Receivables history spans 6 years, with the latest figure at -$788000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 116.83% year-over-year to -$788000.0; the TTM value through Dec 2025 reached -$6.7 million, down 167.89%, while the annual FY2025 figure was -$6.7 million, 167.89% down from the prior year.
  • Change in Receivables reached -$788000.0 in Q4 2025 per RXST's latest filing, up from -$3.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $5.0 million in Q4 2023 to a low of -$3.9 million in Q3 2025.
  • Average Change in Receivables over 5 years is $1.0 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Change in Receivables: surged 566.45% in 2024, then tumbled 1120.94% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $504000.0 in 2021, then skyrocketed by 283.93% to $1.9 million in 2022, then soared by 160.31% to $5.0 million in 2023, then decreased by 7.05% to $4.7 million in 2024, then crashed by 116.83% to -$788000.0 in 2025.
  • Per Business Quant, the three most recent readings for RXST's Change in Receivables are -$788000.0 (Q4 2025), -$3.9 million (Q3 2025), and -$2.9 million (Q2 2025).